The paradoxical activation of the MAPK pathway caused by BRAFV600E inhibitors could be inhibited by dual BRAF-MEK inhibition as has been observed in melanoma, but the consequence of this is expected to be more p-AKT [39]. The gene discussed is BRAF; the disease is melanoma.